Topotecan oral
Products billed under this code include Hycamtin.
Payment limit per 0.25 mg, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Hycamtin.
Payment limit per 0.25 mg, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Hycamtin | Sandoz Inc. | 66758-0101-11 | 10 | $1,254.61 |
| Hycamtin | Sandoz Inc. | 66758-0102-11 | 40 | $5,018.44 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $125.461 | +$0.127 | 0.25 mg | Topotecan oral | v1, posted September 17, 2026 |
| 3Q26 | $125.334 | +$0.11 | 0.25 mg | Topotecan oral | v1, posted September 15, 2026 |
| 2Q26 | $125.224 | +$0.134 | 0.25 mg | Topotecan oral | v1, posted September 15, 2026 |
| 1Q26 | $125.09 | +$0.258 | 0.25 mg | Topotecan oral | v1, posted September 15, 2026 |
| 4Q25 | $124.832 | −$0.069 | 0.25 mg | Topotecan oral | v1, posted September 8, 2026 |
| 3Q25 | $124.901 | +$0.001 | 0.25 mg | Topotecan oral | v1, posted March 10, 2026 |
| 2Q25 | $124.90 | −$0.031 | 0.25 mg | Topotecan oral | v1, posted March 10, 2026 |
| 1Q25 | $124.931 | +$0.071 | 0.25 mg | Topotecan oral | v1, posted December 19, 2025 |
| 4Q24 | $124.86 | +$10.552 | 0.25 mg | Topotecan oral | v1, posted June 11, 2025 |
| 3Q24 | $114.308 | +$1.07 | 0.25 mg | Topotecan oral | v1, posted June 11, 2025 |
| 2Q24 | $113.238 | −$0.253 | 0.25 mg | Topotecan oral | v1, posted March 11, 2025 |
| 1Q24 | $113.491 | −$0.288 | 0.25 mg | Topotecan oral | v1, posted December 19, 2024 |
| 4Q23 | $113.779 | +$1.479 | 0.25 mg | Topotecan oral | v1, posted October 10, 2024 |
| 3Q23 | $112.30 | +$7.932 | 0.25 mg | Topotecan oral | v1, posted June 5, 2024 |
| 2Q23 | $104.368 | +$0.004 | 0.25 mg | Topotecan oral | v1, posted February 23, 2024 |
| 1Q23 | $104.364 | +$0.023 | 0.25 mg | Topotecan oral | v1, posted December 6, 2023 |
| 4Q22 | $104.341 | −$0.017 | 0.25 mg | Topotecan oral | v1, posted June 22, 2023 |
| 3Q22 | $104.358 | +$0.058 | 0.25 mg | Topotecan oral | v1, posted June 9, 2023 |
| 2Q22 | $104.30 | +$0.044 | 0.25 mg | Topotecan oral | v1, posted December 14, 2022 |
| 1Q22 | $104.256 | +$0.511 | 0.25 mg | Topotecan oral | v1, posted June 8, 2022 |
| 4Q21 | $103.745 | −$0.495 | 0.25 mg | Topotecan oral | v1, posted June 2, 2022 |
| 3Q21 | $104.24 | +$0.523 | 0.25 mg | Topotecan oral | v1, posted June 2, 2022 |
| 2Q21 | $103.717 | +$0.124 | 0.25 mg | Topotecan oral | v1, posted March 1, 2022 |
| 1Q21 | $103.593 | – | 0.25 mg | Topotecan oral | v1, posted December 10, 2021 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.